Promising Myosin Inhibitor Findings Presented at AHA

Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.

GRADE meta-analysis: hepatitis A vaccine blocks 96% in pre-exposure vaccination; outbreak response uses millions of doses, but post-exposure prophylaxis evidence is weak.

Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.

Individuals with or at risk for arrhythmogenic cardiomyopathy had no added risk of ventricular arrhythmia from strength training, unlike endurance exercise.

A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.

Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.

Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.

Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.